Archive: 28/12/2017
Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the ...
Dec 28, 2017